3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Increase Fibrinolytic Activity in Rat Aortic Endothelial Cells

Role of Geranylgeranylation and Rho Proteins

From INSERM U 426 and the Department of Physiology, Faculté de Médecine Xavier Bichat, Université Denis Diderot (M.E., D.P., B.E., G.F.), and INSERM U 64, Hopital Tenon (G.N., J.-D.S.), Paris, France.

Correspondence to Dr Marie Essig, INSERM U 426, Faculté de Médecine Xavier Bichat, 16, rue Henri Huchard, F-75018, Paris, France. E-mail essig{at}bichat.inserm.fr

Abstract—3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (HRIs) have been recently shown to prevent atherosclerosis progression. Clinical benefit results from combined actions on various components of the atherosclerotic lesion. This study was designed to identify the effects of HRI on one of these components, the endothelial fibrinolytic system. Aortas isolated from rats treated for 2 days with lovastatin (4 mg/kg body wt per day) showed a 3-fold increase in tissue plasminogen activator (tPA) activity. In a rat aortic endothelial cell line (SVARECs) and in human nontransformed endothelial cells (HUVECs), HRI induced an increase in tPA activity and antigen in a time- and concentration-dependent manner. In SVARECs, the maximal response was observed when cells were incubated for 48 hours with 50 µmol/L HRI. An increase of tPA mRNA was also in evidence. In contrast, HRI inhibited plasminogen activator inhibitor-1 activity and mRNA. The effects of HRI were reversed by mevalonate and geranylgeranyl pyrophosphate, but not by LDL cholesterol and farnesyl pyrophosphate, and were not induced by -hydroxyfarnesyl phosphonic acid, an inhibitor of protein farnesyl transferase. C3 exoenzyme, an inhibitor of the geranylgeranylated-activated Rho protein, reproduced the effect of lovastatin on tPA and plasminogen activator inhibitor-1 activity and blocked its reversal by geranylgeranyl pyrophosphate. The effect of HRI was associated with a disruption of cellular actin filaments without modification of microtubules. A disrupter of actin filaments, cytochalasin D, induced the same effect as lovastatin on tPA, whereas a disrupter of microtubules, nocodazole, did not. In conclusion, HRI can modify the fibrinolytic potential of endothelial cells, likely via inhibition of geranylgeranylated Rho protein and disruption of the actin filaments. The resulting increase of fibrinolytic activity of endothelial cells may contribute to the beneficial effects of HRI in the progression of atherosclerosis.

Key Words: atherosclerosis • plasminogen activator • isoprenoid • Rho protein • endothelium

This article has been cited by other articles:

				F. Arslan, G. Pasterkamp, and D. P. de Kleijn Unraveling Pleiotropic Effects Of Statins: Bit By Bit, a Slow Case With Perspective Circ. Res., August 15, 2008; 103(4): 334 - 336. [Full Text] [PDF]

				Q. Fu, J. Wang, M. Boerma, M. Berbee, X. Qiu, L. M. Fink, and M. Hauer-Jensen Involvement of Heat Shock Factor 1 in Statin-Induced Transcriptional Upregulation of Endothelial Thrombomodulin Circ. Res., August 15, 2008; 103(4): 369 - 377. [Abstract] [Full Text] [PDF]

				Y. Chiba, J. Arima, H. Sakai, and M. Misawa Lovastatin inhibits bronchial hyperresponsiveness by reducing RhoA signaling in rat allergic asthma Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L705 - L713. [Abstract] [Full Text] [PDF]

				C Belizna, A Lartigue, J Favre, D Gilbert, F Tron, H Levesque, C Thuillez, and V Richard Antiphospholipid antibodies induce vascular functional changes in mice: a mechanism of vascular lesions in antiphospholipid syndrome? Lupus, March 1, 2008; 17(3): 185 - 194. [Abstract] [PDF]

				J. Alvarez-Sabin, R. Huertas, M. Quintana, M. Rubiera, P. Delgado, M. Ribo, C. A. Molina, and J. Montaner Prior Statin Use May Be Associated With Improved Stroke Outcome After Tissue Plasminogen Activator Stroke, March 1, 2007; 38(3): 1076 - 1078. [Abstract] [Full Text] [PDF]

				N. N. Boushra and M. Muntazar Review article: The role of statins in reducing perioperative cardiac risk: physiologic and clinical perspectives: [Le role des statines dans la reduction du risque cardiaque perioperatoire : perspectives physiologiques et cliniques]. Can J Anesth, November 1, 2006; 53(11): 1126 - 1147. [Abstract] [Full Text] [PDF]

				S. Ichihara, A. Noda, K. Nagata, K. Obata, J. Xu, G. Ichihara, S. Oikawa, S. Kawanishi, Y. Yamada, and M. Yokota Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure Cardiovasc Res, February 15, 2006; 69(3): 726 - 735. [Abstract] [Full Text] [PDF]

				S. Maeda, I. Matsuoka, T. Iwamoto, H. Kurose, and J. Kimura Down-Regulation of Na+/Ca2+ Exchanger by Fluvastatin in Rat Cardiomyoblast H9c2 Cells: Involvement of RhoB in Na+/Ca2+ Exchanger mRNA Stability Mol. Pharmacol., August 1, 2005; 68(2): 414 - 420. [Abstract] [Full Text] [PDF]

				J. Dong, S. Fujii, H. Li, H. Nakabayashi, M. Sakai, S. Nishi, D. Goto, T. Furumoto, S. Imagawa, T. A.K.M. Zaman, et al. Interleukin-6 and Mevastatin Regulate Plasminogen Activator Inhibitor-1 Through CCAAT/Enhancer-Binding Protein-{delta} Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 1078 - 1084. [Abstract] [Full Text] [PDF]

				T. Senokuchi, T. Matsumura, M. Sakai, M. Yano, T. Taguchi, T. Matsuo, K. Sonoda, D. Kukidome, K. Imoto, T. Nishikawa, et al. Statins Suppress Oxidized Low Density Lipoprotein-induced Macrophage Proliferation by Inactivation of the Small G Protein-p38 MAPK Pathway J. Biol. Chem., February 25, 2005; 280(8): 6627 - 6633. [Abstract] [Full Text] [PDF]

				U. Schonbeck and P. Libby Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents? Circulation, June 1, 2004; 109(21_suppl_1): II-18 - II-26. [Abstract] [Full Text] [PDF]

				L. M. Blanco-Colio, J. L. Martin-Ventura, J. M. Sol, C. Diaz, G. Hernandez, and J. Egido Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: Normalization by atorvastatin J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1188 - 1194. [Abstract] [Full Text] [PDF]

				J. P. Werba, E. Tremoli, P. Massironi, M. Camera, A. Cannata, F. Alamanni, P. Biglioli, and A. Parolari Statins in coronary bypass surgery: rationale and clinical use Ann. Thorac. Surg., December 1, 2003; 76(6): 2132 - 2140. [Abstract] [Full Text] [PDF]

				Z. Mallat, A. Gojova, V. Sauzeau, V. Brun, J.-S. Silvestre, B. Esposito, R. Merval, H. Groux, G. Loirand, and A. Tedgui Rho-Associated Protein Kinase Contributes to Early Atherosclerotic Lesion Formation in Mice Circ. Res., October 31, 2003; 93(9): 884 - 888. [Abstract] [Full Text] [PDF]

				L. M. Blanco-Colio, B. Munoz-Garcia, J. L. Martin-Ventura, C. Lorz, C. Diaz, G. Hernandez, and J. Egido 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Decrease Fas Ligand Expression and Cytotoxicity in Activated Human T Lymphocytes Circulation, September 23, 2003; 108(12): 1506 - 1513. [Abstract] [Full Text] [PDF]

				S S Pierangeli and E N Harris Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells Lupus, July 1, 2003; 12(7): 539 - 545. [Abstract] [PDF]

				S. Wolfrum, K. S. Jensen, and J. K. Liao Endothelium-Dependent Effects of Statins Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 729 - 736. [Abstract] [Full Text] [PDF]

				K. Masamura, K. Oida, H. Kanehara, J. Suzuki, S. Horie, H. Ishii, and I. Miyamori Pitavastatin-Induced Thrombomodulin Expression by Endothelial Cells Acts Via Inhibition of Small G Proteins of the Rho Family Arterioscler. Thromb. Vasc. Biol., March 1, 2003; 23(3): 512 - 517. [Abstract] [Full Text] [PDF]

				A. Rezaie-Majd, G. W. Prager, R. A. Bucek, G. H. Schernthaner, T. Maca, H.-G. Kress, P. Valent, B. R. Binder, E. Minar, and M. Baghestanian Simvastatin Reduces the Expression of Adhesion Molecules in Circulating Monocytes From Hypercholesterolemic Patients Arterioscler. Thromb. Vasc. Biol., March 1, 2003; 23(3): 397 - 403. [Abstract] [Full Text] [PDF]

				P.O Bonetti, L.O Lerman, C Napoli, and A Lerman Statin effects beyond lipid lowering--are they clinically relevant? Eur. Heart J., February 1, 2003; 24(3): 225 - 248. [Full Text] [PDF]

				W. Palinski and C. Napoli Unraveling Pleiotropic Effects of Statins on Plaque Rupture Arterioscler. Thromb. Vasc. Biol., November 1, 2002; 22(11): 1745 - 1750. [Full Text] [PDF]

				C. Kluft, R. Kleemann, and M.P.M. de Maat How best to counteract the enemies? By controlling inflammation in the coronary circulation Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G53 - G65. [Abstract] [PDF]

				J. C. Mason, Z. Ahmed, R. Mankoff, E. A. Lidington, S. Ahmad, V. Bhatia, A. Kinderlerer, A. M. Randi, and D. O. Haskard Statin-Induced Expression of Decay-Accelerating Factor Protects Vascular Endothelium Against Complement-Mediated Injury Circ. Res., October 18, 2002; 91(8): 696 - 703. [Abstract] [Full Text] [PDF]

				N. C. Kraynack, D. A. Corey, H. L. Elmer, and T. J. Kelley Mechanisms of NOS2 regulation by Rho GTPase signaling in airway epithelial cells Am J Physiol Lung Cell Mol Physiol, September 1, 2002; 283(3): L604 - L611. [Abstract] [Full Text] [PDF]

				S. Delbosc, J.-P. Cristol, B. Descomps, A. Mimran, and B. Jover Simvastatin Prevents Angiotensin II-Induced Cardiac Alteration and Oxidative Stress Hypertension, August 1, 2002; 40(2): 142 - 147. [Abstract] [Full Text] [PDF]

				A. Rezaie-Majd, T. Maca, R. A. Bucek, P. Valent, M. R. Muller, P. Husslein, A. Kashanipour, E. Minar, and M. Baghestanian Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients Arterioscler. Thromb. Vasc. Biol., July 1, 2002; 22(7): 1194 - 1199. [Abstract] [Full Text] [PDF]

				R. W. van Etten, E. J.P. de Koning, M. L. Honing, E. S. Stroes, C. A. Gaillard, and T. J. Rabelink Intensive Lipid Lowering by Statin Therapy Does Not Improve Vasoreactivity in Patients With Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., May 1, 2002; 22(5): 799 - 804. [Abstract] [Full Text] [PDF]

				S. Ledoux, D. Laouari, M. Essig, I. Runembert, G. Trugnan, J.B. Michel, and G. Friedlander Lovastatin Enhances Ecto-5'-Nucleotidase Activity and Cell Surface Expression in Endothelial Cells: Implication of Rho-Family GTPases Circ. Res., March 8, 2002; 90(4): 420 - 427. [Abstract] [Full Text] [PDF]

				U. Laufs, H. Kilter, C. Konkol, S. Wassmann, M. Bohm, and G. Nickenig Impact of HMG CoA reductase inhibition on small GTPases in the heart Cardiovasc Res, March 1, 2002; 53(4): 911 - 920. [Abstract] [Full Text] [PDF]

				S. Wassmann, U. Laufs, K. Muller, C. Konkol, K. Ahlbory, A. T. Baumer, W. Linz, M. Bohm, and G. Nickenig Cellular Antioxidant Effects of Atorvastatin In Vitro and In Vivo Arterioscler. Thromb. Vasc. Biol., February 1, 2002; 22(2): 300 - 305. [Abstract] [Full Text] [PDF]

				M. Takemoto and J. K. Liao Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Arterioscler. Thromb. Vasc. Biol., November 1, 2001; 21(11): 1712 - 1719. [Abstract] [Full Text] [PDF]

				M. Essig, F. Terzi, M. Burtin, and G. Friedlander Mechanical strains induced by tubular flow affect the phenotype of proximal tubular cells Am J Physiol Renal Physiol, October 1, 2001; 281(4): F751 - F762. [Abstract] [Full Text] [PDF]

				B. R. Kwak and F. Mach Statins Inhibit Leukocyte Recruitment: New Evidence for Their Anti-Inflammatory Properties Arterioscler. Thromb. Vasc. Biol., August 1, 2001; 21(8): 1256 - 1258. [Full Text] [PDF]

				B. Wong, W. C. Lumma, A. M. Smith, J. T. Sisko, S. D. Wright, and T.-Q. Cai Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation J. Leukoc. Biol., June 1, 2001; 69(6): 959 - 962. [Abstract] [Full Text] [PDF]

				S. Wassmann, U. Laufs, A. T. Baumer, K. Muller, K. Ahlbory, W. Linz, G. Itter, R. Rosen, M. Bohm, and G. Nickenig HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species Hypertension, June 1, 2001; 37(6): 1450 - 1457. [Abstract] [Full Text] [PDF]

				S. Amin-Hanjani, N. E. Stagliano, M. Yamada, P. L. Huang, J. K. Liao, M. A. Moskowitz, C. Y. Hsu, and A. Nassief Mevastatin, an HMG-CoA Reductase Inhibitor, Reduces Stroke Damage and Upregulates Endothelial Nitric Oxide Synthase in Mice Editorial Comment Stroke, April 1, 2001; 32(4): 980 - 986. [Abstract] [Full Text] [PDF]

				G. P. van Nieuw Amerongen and V. W.M. van Hinsbergh Cytoskeletal Effects of Rho-Like Small Guanine Nucleotide-Binding Proteins in the Vascular System Arterioscler. Thromb. Vasc. Biol., March 1, 2001; 21(3): 300 - 311. [Abstract] [Full Text] [PDF]

				O. Feron, C. Dessy, J.-P. Desager, and J.-L. Balligand Hydroxy-Methylglutaryl-Coenzyme A Reductase Inhibition Promotes Endothelial Nitric Oxide Synthase Activation Through a Decrease in Caveolin Abundance Circulation, January 2, 2001; 103(1): 113 - 118. [Abstract] [Full Text] [PDF]

				W. Palinsk New Evidence for Beneficial Effects of Statins Unrelated to Lipid Lowering Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 3 - 5. [Full Text] [PDF]

				U. Laufs, M. Endres, F. Custodis, K. Gertz, G. Nickenig, J. K. Liao, and M. Bohm Suppression of Endothelial Nitric Oxide Production After Withdrawal of Statin Treatment Is Mediated by Negative Feedback Regulation of Rho GTPase Gene Transcription Circulation, December 19, 2000; 102(25): 3104 - 3110. [Abstract] [Full Text] [PDF]

				U. Laufs, K. Gertz, P. Huang, G. Nickenig, M. Bohm, U. Dirnagl, M. Endres, and C. J. Vaughan Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice Editorial Comment Stroke, October 1, 2000; 31(10): 2442 - 2449. [Abstract] [Full Text] [PDF]

				J. S. Alexander Rho, Tyrosine Kinase, Ca2+, and Junctions in Endothelial Hyperpermeability Circ. Res., August 18, 2000; 87(4): 268 - 271. [Full Text] [PDF]

				T. Bourcier and P. Libby HMG CoA Reductase Inhibitors Reduce Plasminogen Activator Inhibitor-1 Expression by Human Vascular Smooth Muscle and Endothelial Cells Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 556 - 562. [Abstract] [Full Text] [PDF]

				J. W. Fenton, G. X. Shen, F. L. Minnear, D. V. Brezniak, J. M. Walenga, J. J. Bognacki, and F. A. Ofosu State-of-the-Art-Review : Statins Induce Hypothrombotic States? Clinical and Applied Thrombosis/Hemostasis, January 1, 2000; 6(1): 18 - 21. [Abstract] [PDF]

				A. H. Wagner, T. Kohler, U. Ruckschloss, I. Just, and M. Hecker Improvement of Nitric Oxide-Dependent Vasodilatation by HMG-CoA Reductase Inhibitors Through Attenuation of Endothelial Superoxide Anion Formation Arterioscler. Thromb. Vasc. Biol., January 1, 2000; 20(1): 61 - 69. [Abstract] [Full Text] [PDF]

				H.-J. Park and J. B. Galper 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase PNAS, September 28, 1999; 96(20): 11525 - 11530. [Abstract] [Full Text] [PDF]

				A. Hahn, J. Heusinger-Ribeiro, T. Lanz, S. Zenkel, and M. Goppelt-Struebe Induction of Connective Tissue Growth Factor by Activation of Heptahelical Receptors. MODULATION BY Rho PROTEINS AND THE ACTIN CYTOSKELETON J. Biol. Chem., November 22, 2000; 275(48): 37429 - 37435. [Abstract] [Full Text] [PDF]

				S. Ledoux, D. Laouari, M. Essig, I. Runembert, G. Trugnan, J.B. Michel, and G. Friedlander Lovastatin Enhances Ecto-5'-Nucleotidase Activity and Cell Surface Expression in Endothelial Cells: Implication of Rho-Family GTPases Circ. Res., March 8, 2002; 90(4): 420 - 427. [Abstract] [Full Text] [PDF]